Questioning the Consensus on Placebo and Nocebo Effects.
Questioning the Consensus on Placebo and Nocebo Effects.
复制标题
质疑安慰剂和反安慰剂效应的共识。
DOI:
10.1159/000513466
复制
发表时间:
2021
影响因子:
22.8
通讯作者:
Hardman D
中科院分区:
文献类型:
--
作者:
Hardman D
We read with interest a recent article in Psychotherapy and Psychosomatics reporting the consensus of 27 experts on what should be communicated to patients about placebo and nocebo effects and how clinicians should be trained to deliver this information [1]. The authors propose that communicating general information to patients about placebo and nocebo effects is beneficial but should be adjusted to the context. They further propose that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education. These recommendations build on an earlier consensus statement regarding maximizing placebo effects and minimizing nocebo effects in clinical practice [2]. In response, we argue that the latest consensus statement is conceptually ambiguous and does not accord with recent research on the views of patients and clinicians. Furthermore, the presentation of these consensus statements belies lively debates and disagreements in placebo study research, including on fundamental issues such as the dominance of cognitivist accounts of placebo and nocebo effects [3, 4]. As the authors note, their method did not allow them to draw conclusions about specific strategies that can maximize placebo effects and minimize nocebo effects.This is, of course, because “placebo” and “nocebo” are merely umbrella terms that, though useful for coordinating research, encompass a diverse array of situation-dependent practices too numerous to mention–practices that patients and clinicians engage in and talk about without the need for abstract umbrella terms. As a previous